EWTX
Edgewise Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$43.07
+2.67%0
Insider buys (3m)
21
Insider sells (3m)
-$9.8M
Net value (3m)
+19.3%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Aug 17, 2026 | Russell Alan J · director, officer: Chief Scientific Officer | A-Award | 65,000 | $44 |
| Aug 17, 2026 | MOORE JOHN R · officer: General Counsel | A-Award | 65,000 | $44 |
| Aug 17, 2026 | Nofi Michael · officer: Chief Financial Officer | A-Award | 48,750 | $44 |
| Aug 17, 2026 | Derakhshan Behrad · officer: Chief Business Officer | A-Award | 100,000 | $44 |
| Aug 17, 2026 | Donovan Joanne M. · officer: CMO | A-Award | 65,000 | $44 |
| Aug 14, 2026 | KOCH KEVIN · director, officer: President and CEO | A-Award | 100,000 | $0.00 |
| Aug 14, 2026 | KOCH KEVIN · director, officer: President and CEO | A-Award | 200,000 | $44 |
| Aug 14, 2026 | Donovan Joanne M. · officer: CMO | Sale | 2,839 | $44 |
| Aug 14, 2026 | Donovan Joanne M. · officer: CMO | Sale | 2,779 | $44 |
| Aug 14, 2026 | Donovan Joanne M. · officer: CMO | Sale | 104 | $44 |
| Aug 14, 2026 | Donovan Joanne M. · officer: CMO | Sale | 800 | $45 |
| Aug 14, 2026 | Donovan Joanne M. · officer: CMO | Sale | 2,919 | $43 |
| Aug 14, 2026 | Donovan Joanne M. · officer: CMO | A-Award | 32,500 | $0.00 |
| Aug 14, 2026 | Donovan Joanne M. · officer: CMO | A-Award | 65,000 | $0.00 |
| Aug 14, 2026 | Russell Alan J · director, officer: Chief Scientific Officer | M-Exempt | 5,781 | $0.00 |
| Aug 14, 2026 | Russell Alan J · director, officer: Chief Scientific Officer | M-Exempt | 7,031 | $0.00 |
| Aug 14, 2026 | Russell Alan J · director, officer: Chief Scientific Officer | Sale | 3,238 | $44 |
| Aug 14, 2026 | Russell Alan J · director, officer: Chief Scientific Officer | Sale | 2,273 | $44 |
| Aug 14, 2026 | Russell Alan J · director, officer: Chief Scientific Officer | Sale | 390 | $44 |
| Aug 14, 2026 | Russell Alan J · director, officer: Chief Scientific Officer | A-Award | 32,500 | $0.00 |
| Aug 14, 2026 | Russell Alan J · director, officer: Chief Scientific Officer | A-Award | 65,000 | $0.00 |
| Aug 14, 2026 | MOORE JOHN R · officer: General Counsel | M-Exempt | 5,781 | $0.00 |
| Aug 14, 2026 | MOORE JOHN R · officer: General Counsel | M-Exempt | 6,718 | $0.00 |
| Aug 14, 2026 | MOORE JOHN R · officer: General Counsel | Sale | 2,439 | $44 |
| Aug 14, 2026 | MOORE JOHN R · officer: General Counsel | Sale | 59 | $44 |
| Aug 14, 2026 | MOORE JOHN R · officer: General Counsel | Sale | 99 | $45 |
| Aug 14, 2026 | MOORE JOHN R · officer: General Counsel | Sale | 2,419 | $44 |
| Aug 14, 2026 | MOORE JOHN R · officer: General Counsel | A-Award | 32,500 | $0.00 |
| Aug 14, 2026 | MOORE JOHN R · officer: General Counsel | A-Award | 65,000 | $0.00 |
| Aug 14, 2026 | Derakhshan Behrad · officer: Chief Business Officer | M-Exempt | 5,781 | $0.00 |
Institutional positioning
13F filings over the trailing two quarters
New 86Increased 153Reduced 144Sold out 27
| Filer | Action | Shares | Filed |
|---|---|---|---|
| ORBIMED ADVISORS LLC | Unchanged | 15,518,492 | May 15, 2026 |
| ORBIMED ADVISORS LLC | Unchanged | 15,518,492 | Aug 14, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | Unchanged | 10,428,437 | May 15, 2026 |
| Paradigm Biocapital Advisors LP | Increased | 10,215,455 | Aug 14, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | Reduced | 8,392,730 | Aug 14, 2026 |
| PARADIGM BIOCAPITAL ADVISORS LP | Increased | 7,365,038 | May 15, 2026 |
| BlackRock, Inc. | Increased | 6,606,336 | Aug 7, 2026 |
| BAKER BROS. ADVISORS LP | Unchanged | 6,575,940 | May 15, 2026 |
| BLACKROCK, INC. | Reduced | 6,472,991 | May 13, 2026 |
| Jupiter Topco LLC | New Position | 6,075,331 | Aug 14, 2026 |
| JANUS HENDERSON GROUP PLC | Increased | 5,915,556 | May 18, 2026 |
| FMR LLC | Increased | 5,489,135 | Aug 13, 2026 |
| Novo Holdings A/S | Unchanged | 5,350,000 | Aug 14, 2026 |
| NOVO HOLDINGS A/S | Unchanged | 5,350,000 | May 15, 2026 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | Increased | 4,728,623 | Aug 14, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Aug 17, 2026